association

Full identifier: http://purl.org/np/RA8JEKnKA7dO0F-pnWTVe4YaGMjh_mfnOX5wwDymAk6lg#association

Assigned to 1 class:

Minted in Nanopublication

 RA8JEKnKA7 comment approve/disapprove edit as derived nanopublication create new with same template

This is a local identifier minted within the nanopublication. http://purl.org/np/RA8JEKnKA7...#association This association http://www.w3.org/2000/01/rdf-schema#label has label (this is a literal) "zoledronic acid injection is a bisphosphonate indicated for zoledronic acid injection is indicated for treatment of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis diagnosed by bone mineral density bmd or prevalent vertebral fracture zoledronic acid injection reduces the incidence of fractures hip vertebral and non vertebral osteoporosis related fractures in patients at high risk of fracture defined as a recent low trauma hip fracture zoledronic acid injection reduces the incidence of new clinical fractures see clinical studies 14 1 zoledronic acid injection is indicated for prevention of osteoporosis in postmenopausal women see clinical studies 14 2 zoledronic acid injection is indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 14 3 zoledronic acid injection is indicated for the treatment and prevention of glucocorticoid induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months see clinical studies 14 4 zoledronic acid injection is indicated for treatment of paget s disease of bone in men and women treatment is indicated in patients with paget s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age specific normal reference range or those who are symptomatic or those at risk for complications from their disease see clinical studies 14 5 the safety and effectiveness of zoledronic acid injection for the treatment of osteoporosis is based on clinical data of three years duration the optimal duration of use has not been determined all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8JEKnKA7... This nanopublication date and time when the nanopublication was created http://purl.org/dc/terms/created was created on (this is a literal) "2021-07-03T11:29:26.679+02:00" .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8JEKnKA7... This nanopublication links to the assertion template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate was created from the assertion template http://purl.org/np/RAManV5GZI... RAManV5GZI .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8JEKnKA7... This nanopublication links to the provenance template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate was created from the provenance template http://purl.org/np/RANwQa4ICW... RANwQa4ICW .
This is the identifier for this whole nanopublication. http://purl.org/np/RA8JEKnKA7... This nanopublication links to the publication info template that was used to create this nanopublication https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate was created from the publication info template http://purl.org/np/RAA2MfqdBC... RAA2MfqdBC .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA8JEKnKA7...#sig sig http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RA8JEKnKA7... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RA8JEKnKA7...#sig sig http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal) "RSA" .

Leoni Bücken, 3 Jul 2021, 09:29:26 UTC

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:29:26.679Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
zoledronic acid injection is a bisphosphonate indicated for zoledronic acid injection is indicated for treatment of osteoporosis in postmenopausal women in postmenopausal women with osteoporosis diagnosed by bone mineral density bmd or prevalent vertebral fracture zoledronic acid injection reduces the incidence of fractures hip vertebral and non vertebral osteoporosis related fractures in patients at high risk of fracture defined as a recent low trauma hip fracture zoledronic acid injection reduces the incidence of new clinical fractures see clinical studies 14 1 zoledronic acid injection is indicated for prevention of osteoporosis in postmenopausal women see clinical studies 14 2 zoledronic acid injection is indicated for treatment to increase bone mass in men with osteoporosis see clinical studies 14 3 zoledronic acid injection is indicated for the treatment and prevention of glucocorticoid induced osteoporosis in men and women who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7 5 mg or greater of prednisone and who are expected to remain on glucocorticoids for at least 12 months see clinical studies 14 4 zoledronic acid injection is indicated for treatment of paget s disease of bone in men and women treatment is indicated in patients with paget s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age specific normal reference range or those who are symptomatic or those at risk for complications from their disease see clinical studies 14 5 the safety and effectiveness of zoledronic acid injection for the treatment of osteoporosis is based on clinical data of three years duration the optimal duration of use has not been determined all patients on bisphosphonate therapy should have the need for continued therapy re evaluated on a periodic basis patients at low risk for fracture should be considered for drug discontinuation after 3 to 5 years of use patients who discontinue therapy should have their risk for fracture re evaluated periodically
Leoni Bücken
2021-07-03T09:29:26.679Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:29:26.679Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:29:26.679Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:29:26.679Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:29:26.679Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:29:26.679Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-07-03T09:29:26.679Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)